Edition:
India

miRagen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

5.48USD
2:29am IST
Change (% chg)

$0.08 (+1.48%)
Prev Close
$5.40
Open
$5.46
Day's High
$5.55
Day's Low
$5.39
Volume
39,782
Avg. Vol
63,866
52-wk High
$17.83
52-wk Low
$5.01

Chart for

About

Miragen Therapeutics, Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical product... (more)

Overall

Beta: 1.97
Market Cap(Mil.): $202.81
Shares Outstanding(Mil.): 21.48
Dividend: --
Yield (%): --

Financials

BRIEF-Miragen Therapeutics Prices Public Offering Of Common Stock

* MIRAGEN THERAPEUTICS, INC. PRICES PUBLIC OFFERING OF COMMON STOCK

09 Feb 2018

BRIEF-miRagen Therapeutics Announces Proposed Public Offering Of Common Stock

* MIRAGEN THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

05 Feb 2018

BRIEF-Miragen Therapeutics reports third quarter financial results

* Miragen Therapeutics reports third quarter 2017 financial results and provides corporate update

09 Nov 2017

BRIEF-Miragen Therapeutics presents new data suggesting positive impact from systemically administered MRG-106

* Miragen Therapeutics presents new clinical data suggesting positive impact from systemically administered MRG-106 on mycosis fungoides form of cutaneous T-cell lymphoma at EORTC global task force meeting

13 Oct 2017

BRIEF-Miragen Therapeutics presents new MRG-201 preclinical data

* Miragen Therapeutics presents new MRG-201 preclinical data for Inhaled Microrna-29 Mimic Targeting Pulmonary Fibrosis Source text for Eikon: Further company coverage:

12 Sep 2017

Earnings vs. Estimates